Dhakal Recaps Findings From the CARTITUDE-4 Study

Binod Dhakal, MD, MS, assistant professor of medicine in the Division of Hematology and Oncology at the Medical College of Wisconsin, discusses results from the phase 3 CARTITUDE-4 study (NCT04181827) of ciltacabtagene autoleucel (cilta-cel; Carvykti) in patients with lenalidomide-refractory multiple myeloma.

Cilta-cel achieved a 74% reduction in the risk of disease progression or death compared with standard of care treatment in CARTITUDE-4, according to a presentation given by Dhakal at the 2023 American Society of Clinical Oncology Annual Meeting.

Dhakal says the results show that cilta-cel is highly effective for treating lenalidomide-refractory multiple myeloma. In addition to the progression-free survival advantage, the response rate, and minimal disease negativity rate shown with cilta-cel were also positive.

Transcript:

0:07 | The primary end point of the study was progression-free survival, and we saw cilta-cel significantly reduced the risk of disease progression or death vs standard-of-care by 74%. The hazard ratio was 0.26. The median PFS at 16 months follow-up was not reached in the cilta-cel arm compared with 11.8 months in the standard-of-care arm, and the 12-month PFS rates were 76% in the cilta-cel arm compared with 49% in the standard-of-care arm. We also observed that cilta-cel consistently prolonged the progression-free survival in all subgroups, including the key subgroups of patients with high-risk disease, soft tissue plasmacytoma, and triple-class refractory disease.

0:52 | Cilta-cel led to significantly higher rates of response and default response compared with standard-of-care. The overall response rates are 85% and better in patients with cilta-cel vs 67% with the standard-of-care. When looking at the MRD negativity and the complete response rates, the complete response rates were 72% in the cilta-cel arm vs 22% in the standard-of-care arm, and MRD negativity rates for all patients were 61% in the cilta-cel arm vs 16% in the standard-of-care arm. These results suggest cilta-cel is highly effective and provides superior efficacy responses compared with standard-of-care in the study.